With decades of experience in interventional cardiology, structural heart, and cardiac imaging, we’re committed to advancing patient outcomes. Join us at TCT 2025 in San Francisco, Oct 25–28. https://ow.ly/YKFk50XeRv4 #...
Press releases
-
ICON plc schedules second quarter 2023 earnings conference call
ICON plc will release its financial results for the second quarter 2023 after the market closes on Wednesday, July 26, 2023
-
ICON releases latest version of its Digital Platform
ICON plc today announced the latest release of its Digital Platform.
-
ICON plc set to join Russell 3000® Index
ICON plc is set to join the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution.
-
ICON releases its 2022 ICON Cares ESG report
ICON announced the release of its ICON Cares 2022 Environmental, Social and Governance (ESG) Report.
-
ICON reports first quarter 2023 results
Revenue for the first quarter was $1,978.6 million. This represents an increase of 4.0% on prior year revenue or 5.3% on a constant currency organic basis.
-
LEO Pharma and ICON enter a strategic partnership to propel clinical trial execution within medical dermatology
Leo Pharma Group and ICON plc today announced a strategic partnership to improve dermatology patients' lives through innovative clinical trials.
-
ICON plc to present at upcoming investor conferences
Mr. Brendan Brennan, CFO of ICON plc, will present at the 2023 Citi Healthcare Conference and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays Global Healthcare Conference.
-
ICON reports fourth quarter and full year 2022 results
Full year net business wins of $9,450 million; a net book to bill of 1.22.
-
ICON issues financial guidance for full year 2023
ICON plc announced today its financial guidance for the year ending December 31, 2023.
